# Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma

> **NCT03426891** · PHASE1 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 21 (actual)

## Conditions studied

- Glioblastoma
- Brain Tumor
- GBM

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Vorinostat
- **DRUG:** Temozolomide
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT03426891
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2021-10-18
- **Final completion:** 2023-06-28
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2025-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426891, "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03426891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*